
Dermatology
Latest News
Latest Videos

CME Content
More News

The lotion, Duobrii, combines halobetasol propionate, a topical steroid, with tazarotene, a retinoid, to provide 2 mechanisms of action for treating plaque psoriasis.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.

Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.

An examination of the physical, emotional and social burden of psoriasis, and the continued need for research to advance care for patients.

Onychomycosis—fungal infection of the nail—is a common medical problem. Treatments are widely available, but relapse is common.

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.

Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.

Recommendations for acne treatment drawn from AAD position paper and presentations.

The biologic has been previously approved for adult atopic dermatitis and uncontrolled asthma, and is being assesed for another half-dozen allergic/immunologic indications.

Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.

The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.

Confocal microscopy is especially useful for diagnosing pigmented lesions, moles, melanoma, and basal cell carcinoma.

Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.

The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.

A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.

Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.

This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.

Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.

Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.

The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.

Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.




















































